Kazia Therapeutics (KZIA) Price & Analysis

Compare

325 Followers

KZIA Stock Chart & Stats

$13.08

-$0.01(-0.57%)

At close: Jan 08 4:00 PM EST

$13.08

-$0.01(-0.57%)

Day’s Range― - ―

52-Week Range$2.86 - $21.00

Previous CloseN/A

Volume31.49K

Average Volume (3M)209.48K

Market Cap

$12.80M

Enterprise ValueN/A

Total Cash (Recent Filing)$3.06M

Total Debt (Recent Filing)$140.74K

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Aug 28, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,670,578

10 Day Avg. Volume60,839

30 Day Avg. Volume209,481

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$19.00

Price Target Upside45.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessEncouraging early signal in TNBC with a 76% tumor volume shrinkage in the first patient treated in the study, indicating promising results for the treatment of triple-negative breast cancer.

Financial PositionFinancial overhang removed with an equity raise of approximately $50M, significantly improving the company's financial position.

Market OpportunityThe potential for paxalisib to resensitize breast cancer tumors to immunotherapies could represent a significant market opportunity.

Bears Say

Clinical Trial ChallengesPaxalisib did not meet the primary endpoint in its Phase 2 studies, which may be a point of contention with the FDA.

Financial PerformanceKazia reported F2H25 results with a net loss of ($10.2M) and ended the period with $4.3M in cash and equivalents.

Regulatory UncertaintyThere is uncertainty about the success of the path for paxalisib's accelerated approval, as it missed the primary endpoint.

Kazia Therapeutics News

Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kazia Therapeutics (KZIA) to $18 from $13 and keeps a...

1d ago

KZIA

Kazia Therapeutics announces presentation from paxalisib studies

Kazia Therapeutics (KZIA) announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium, or...

3d ago

KZIA

Kazia Therapeutics trading resumes

09:43 EST Kazia Therapeutics (KZIA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

11d ago

KZIA

Kazia Therapeutics trading halted, volatility trading pause

09:38 EST Kazia Therapeutics (KZIA) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

11d ago

KZIA

Kazia Therapeutics announces pricing of $50M private placement

Kazia Therapeutics (KZIA) announced that it has entered into a securities purchase agreement with certain established institutional and...

11d ago

KZIA

Closing Bell Movers: Plug Power slips after converible notes offering

U.S. equity futures were slightly higher following sharp declines during the session, as investors digest a growing hang-up...

25d ago

CEG

CARV

Kazia reports results from patient with stage IV TNBC treated with pembrolizumab

Kazia Therapeutics (KZIA) announced that a patient with stage IV triple-negative breast cancer, or TNBC, treated under an...

25d ago

KZIA

Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium

The latest update is out from Kazia Therapeutics ( ($KZIA) ). On December 10, 2025, Kazia Therapeutics announced...

3d ago

KZIA

Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance

Kazia Therapeutics ( ($KZIA) ) has issued an announcement. On December 2, 2025, Kazia Therapeutics Limited entered into...

8d ago

KZIA

Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development

An update from Kazia Therapeutics ( ($KZIA) ) is now available. On December 2, 2025, Kazia Therapeutics announced...

11d ago

KZIA

Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Kazia Therapeutics, with...

24d ago

KZIA

Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline

Kazia Therapeutics ( ($KZIA) ) has provided an update. Kazia Therapeutics Limited announced that it received a staff...

25d ago

KZIA

Kazia Therapeutics Delays 20-F Filing

Kazia Therapeutics ( ($KZIA) ) has released a notification of late filing. Kazia Therapeutics Limited has announced a...

1M ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts

Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics yesterday and set a price target...

2M ago

KZIA

KZIA FAQ

What was Kazia Therapeutics Limited’s price range in the past 12 months?

Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $21.00 in the past 12 months.

What is Kazia Therapeutics Limited’s market cap?

Kazia Therapeutics Limited’s market cap is $12.80M.

When is Kazia Therapeutics Limited’s upcoming earnings report date?

Kazia Therapeutics Limited’s upcoming earnings report date is Aug 28, 2025 which is 107 days ago.

How were Kazia Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is Kazia Therapeutics Limited overvalued?

According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kazia Therapeutics Limited pay dividends?

Kazia Therapeutics Limited does not currently pay dividends.

What is Kazia Therapeutics Limited’s EPS estimate?

Kazia Therapeutics Limited’s EPS estimate is >-0.01.

How many shares outstanding does Kazia Therapeutics Limited have?

Kazia Therapeutics Limited has 1,670,578 shares outstanding.

What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kazia Therapeutics Limited?

Currently, no hedge funds are holding shares in KZIA

Company Description

Kazia Therapeutics Limited

Kazia Therapeutics Limited (KZIA) is an innovative oncology-focused biotechnology company based in Australia. It is dedicated to the development and commercialization of novel therapeutics for the treatment of cancer. The company's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is currently in clinical trials for glioblastoma, a highly aggressive form of brain cancer. Kazia Therapeutics aims to address unmet medical needs by advancing its drug candidates through rigorous clinical trials and regulatory processes.

Kazia Therapeutics (KZIA) Earnings & Revenues

Historic Earnings Reports

KZIA Stock 12 Month Forecast

Average Price Target

$19.00

▲(45.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","97":"$97","25.75":"$25.8","49.5":"$49.5","73.25":"$73.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,25.75,49.5,73.25,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,9.984615384615385,10.819230769230769,11.653846153846153,12.48846153846154,13.323076923076922,14.157692307692308,14.992307692307692,15.826923076923077,16.661538461538463,17.496153846153845,18.330769230769228,19.165384615384617,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,9.907692307692308,10.665384615384616,11.423076923076923,12.180769230769231,12.938461538461539,13.696153846153846,14.453846153846154,15.211538461538462,15.96923076923077,16.72692307692308,17.484615384615385,18.24230769230769,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,9.830769230769231,10.511538461538462,11.192307692307693,11.873076923076923,12.553846153846155,13.234615384615385,13.915384615384616,14.596153846153847,15.276923076923078,15.957692307692309,16.638461538461538,17.31923076923077,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >